Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Theradex Oncology US Inquiry
CONTACT
Theradex Oncology EU Inquiry
CONTACT
Lead
Michael Savona
With
Current Arm: ASTX727 + ruxolitinib (JAK1/JAK2 inhibitor) Primary Objective Phase 2: \- To test whether the overall response to each novel ASTX727 combination therapy in MDS/MPN patients is sufficiently high to warrant further investigation in more definitive trials. Secondary Objectives: * To expand the safety analysis of each treatment combination in MDS/MPN patients. * To assess the morphologic bone marrow response in MDS/MPN patients treated on each Arm of the study. * To estimate the effect of each treatment combination on patient survival * To test the applicability of the proposed MDS/MPN IWG response criteria across multiple Arms of this study. Tertiary/Exploratory objectives: * To investigate genetic biomarkers of response in MDS/MPN. * To characterize molecular responses to individual treatments. * To evaluate synergistic effects of hypomethylation by ASTX727 and specific pathway blockade by study compounds. * To explore the use of automated quantification of spleen volume from CT exams as a measure of clinical benefit * To test and/or validate diagnostic algorithms and prognostic indices for MDS/MPN patients * To investigate the correlation of patient reported outcomes with disease severity and/or treatment response
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted